Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2014


ADC Summit 2014 London

19 May 2014 - 20 May 2014 - London, UK



Bookmark and Share


Making your smart bomb smarter - creating innovative antibody-drug conjugates

SMi’s 3rd annual Antibody Drug Conjugates Summit comes at the perfect time to focus on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, bringing together key industry experts from academia, pharma and biotech companies.

Join us this May in London to hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.

KEY REASONS TO ATTEND:

  • Hear cutting edge presentations and key case studies from leading ADCs experts on key topics such as nano-delivery systems, advancing preclinical development to accelerate ADCs into the clinic, next generation ADCs and manufacturing challenges
  • Network and learn from industry and academic opinion leaders including Photobiotics, Medlmmune, Spirogen, Synthon plus many more…
  • Learn about latest developments pertaining to the components of ADCs (payload, antibody and linker)
  • Join the debate in our round table session to discuss creative strategies in making the “smart bomb” more intelligent when building your oncology arsenal

KEY SPEAKERS WILL INCLUDE:

  • Dr Mahendra Deonarain, Chief Scientific Officer, Photobiotics
  • Dr Adeela Kamal, Associate Director, R&D, Oncology Research, MedImmune
  • Philip Howard, PhD, Chief Scientific Officer, Spirogen Limited
  • Dr Trevor Hallam, Chief Scientific Officer, Sutro Biopharma
  • Dr Ronald Elgersma, Project Leader, Antibody-Drug Conjugates, Synthon
  • Dr Erica Hong, Scientist, ImmunoGen
  • Dr Hagop Youssoufian, Executive Vice President of R&D, Progenics
  • Dr Pamela Trail, Vice President Oncology, Regeneron

This 2 day networking event will invite in depth discussion of key drivers impacting ADCs, providing a fantastic opportunity to hear from and talk to professionals currently operating in the market. 

To download a brochure and to secure your attendance visit http://www.smi-online.co.uk/goto/2014adcsummit36.asp 

Alternatively for further information contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk 



Further information
Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!